摘要Alzheimer's disease is a common neurodegenerative disease characterized by progressive memory loss,cognitive decline,and behavioral changes.Blood-based biomarkers have recently gained significant attention due to their accessibility and cost-effectiveness.This review highlights the latest progress in multiple key areas of blood-based biomarkers for Alzheimer's disease.For early diagnosis,blood-based biomarkers such as amyloid-β and phosphorylated tau can identify Alzheimer's disease even before clinical symptoms emerge.Dynamic changes in blood-based biomarkers,including p-tau217 and neurofilament light chain,reflect disease progression and correlate with cognitive decline,enabling continuous monitoring of Alzheimer's disease progression.Additionally,blood-based biomarkers such as p-tau181 and glial fibrillary acidic protein aid in differential diagnosis by distinguishing Alzheimer's disease from other dementias such as frontotemporal dementia.Blood-based biomarkers related to nerve repair have opened up new avenues for tracking nerve regeneration and therapeutic response,especially brain-derived neurotrophic factor.Furthermore,advanced detection technologies such as single-molecule array and immunoprecipitation-mass spectrometry have significantly improved the sensitivity and specificity of blood-based biomarkers,facilitating their clinical translation.In summary,blood-based biomarkers hold strong potential to improve early diagnosis,monitor progression,differential diagnosis,and evaluate therapies in Alzheimer's disease.This review provides a comprehensive and updated evaluation of the translational potential of blood-based biomarkers,emphasizing their practical utility in clinical settings and offering insights into future directions for large-scale application.This review emphasizes the need to prioritize the allocation of scientific resources,expedite the transition of blood-based biomarkers to clinical implementation,and ultimately achieve precise treatment of Alzheimer's disease using these biomarkers.